## SARS-CoV-2 3CLpro-IN-6

**BIOLOGICAL ACTIVITY** 

Cat. No.:	HY-152005
CAS No.:	302821-53-0
Molecular Formula:	C <sub>22</sub> H <sub>15</sub> NO <sub>7</sub>
Molecular Weight:	405.36
Target:	SARS-CoV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.


Description	SARS-CoV-2 3CLpro-IN-6 is a reversible covalent inhibitor of SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro-IN-6 has potent inhibitory activity for SARS-CoV-2 3CL <sup>pro</sup> with an IC <sub>50</sub> value of 4.9 μM. SARS-CoV-2 3CLpro-IN-6 can be used for the research of coronavirus disease 2019 (COVID-19) <sup>[1]</sup> .
IC <sub>50</sub> & Target	IC50: 4.9 μM (SARS-CoV-2 3CL <sup>pro</sup> ) <sup>[1]</sup>
In Vitro	SARS-CoV-2 3CLpro-IN-6 (Compound 13) (0-100 μM) has potent inhibitory activity for SARS-CoV-2 3CL <sup>pro</sup> with IC <sub>50</sub> value of 4.9 μM <sup>[1]</sup> . SARS-CoV-2 3CLpro-IN-6 (5, 10 μM) has typical covalent inhibition behavior with time-dependent activity <sup>[1]</sup> .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Liying Wang, et al. Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen. Eur J Med Chem. 2022 Dec 15;244:114803.





Product Data Sheet

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA